The stock of Ginkgo Bioworks Holdings Inc (DNA) has gone down by -11.22% for the week, with a -10.40% drop in the past month and a -37.06% drop in the past quarter. The volatility ratio for the week is 6.28%, and the volatility levels for the past 30 days are 8.06% for DNA. The simple moving average for the past 20 days is -9.90% for DNA’s stock, with a -21.90% simple moving average for the past 200 days.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
Additionally, the 36-month beta value for DNA is 1.30. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 1 rating it as “sell.”
The public float for DNA is 37.41M and currently, short sellers hold a 31.09% ratio of that float. The average trading volume of DNA on May 22, 2025 was 1.43M shares.
DNA) stock’s latest price update
Ginkgo Bioworks Holdings Inc (NYSE: DNA)’s stock price has plunge by -7.98relation to previous closing price of 7.40. Nevertheless, the company has seen a -11.22% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-21 that BOSTON, May 21, 2025 /PRNewswire/ — Ginkgo Bioworks (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company’s Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company’s Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk’s resignation.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at -5.84% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.99% of loss for the given period.
Volatility was left at 8.06%, however, over the last 30 days, the volatility rate increased by 6.28%, as shares sank -12.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.01% upper at present.
During the last 5 trading sessions, DNA fell by -10.69%, which changed the moving average for the period of 200-days by -43.63% in comparison to the 20-day moving average, which settled at $7.56. In addition, Ginkgo Bioworks Holdings Inc saw -30.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $7.15 back on May 22 ’25. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $708 using the latest closing price.
Dmytruk Mark E., the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 706 shares at $7.58 during a trade that took place back on May 21 ’25, which means that Dmytruk Mark E. is holding shares at $5,355 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -1.98 for the present operating margin
- 0.74 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -1.99. The total capital return value is set at -0.4. Equity return is now at value -57.76, with -32.84 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is -5007.69.
Currently, EBITDA for the company is -484.39 million with net debt to EBITDA at -0.32. When we switch over and look at the enterprise to sales, we see a ratio of 2.17. The receivables turnover for the company is 8.74for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.88.
Conclusion
In conclusion, Ginkgo Bioworks Holdings Inc (DNA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
